2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomes
2021
Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction
Nóbrega O, Campos-Staffico A, Oliveira E, Munhoz D, Moura F, Carvalho L, Soares A, Gomes C, Tonet-Furioso A, Sposito A, . Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction. International Journal Of General Medicine 2021, 14: 3669-3676. PMID: 34321912, PMCID: PMC8312503, DOI: 10.2147/ijgm.s313661.Peer-Reviewed Original ResearchST-elevation myocardial infarctionFlow-mediated dilationNeuronal nitric oxide synthaseAcute phaseInsulin-resistant statesDefective allelesAssociated with poorer endothelial functionInsulin resistanceMyocardial infarctionAssociated with insulin-resistant statesInsulin sensitivityCirculating NO poolB cell functionAcute phase of myocardial infarctionNitric oxidePlasma NO levelsPredictors of mortalityPhase of myocardial infarctionPoorer endothelial functionBlood glucose balanceInfluence insulin responsivenessNitric oxide synthaseConsecutive patientsAA patientsGlycemic disordersDapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2019
P4626Neuronal nitric oxide sintetase polymorphism increases sympathetic activity and recurrent cardiovascular events after myocardial infarction
Oliveira E, Munhoz D, Carvalho L, Moura F, Machado-Silva W, Figueiredo V, Nobrega O, Sposito A. P4626Neuronal nitric oxide sintetase polymorphism increases sympathetic activity and recurrent cardiovascular events after myocardial infarction. European Heart Journal 2019, 40: ehz745.1008. DOI: 10.1093/eurheartj/ehz745.1008.Peer-Reviewed Original ResearchST-elevation myocardial infarctionMajor cardiovascular eventsT allele carriersFlow-mediated dilationRecurrent major cardiovascular eventsCardiovascular eventsSympathetic activityClinical impactT alleleAcute phase of ST-elevation myocardial infarctionAssociated with increased sympathetic toneDecreased FMDMyocardial infarctionClinical follow-upCox regression analysisIncreased sympathetic activityNitric oxideRecurrent cardiovascular eventsAutonomic nervous system modulationCardiac sudden deathElevation myocardial infarctionDecreased parasympathetic activityPeripheral nervous systemSimvastatin doseSympathetic tone
2017
Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly
Campos A, Moura F, Santos S, Freitas W, Sposito A, Study O. Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly. Atherosclerosis 2017, 258: 138-144. PMID: 28129889, DOI: 10.1016/j.atherosclerosis.2017.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdiposityAge FactorsAged, 80 and overAsymptomatic DiseasesBody CompositionCoronary AngiographyCoronary Artery DiseaseCross-Sectional StudiesEndothelium, VascularEnergy IntakeExercise TestExercise ToleranceFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultidetector Computed TomographyMultivariate AnalysisMuscle StrengthMuscle, SkeletalNutrition AssessmentNutritional StatusOdds RatioOverweightProspective StudiesRisk FactorsSarcopeniaVasodilationWeight GainConceptsCoronary heart diseaseAssociated with subclinical atherosclerosisCoronary calcium scoreFlow-mediated dilationExcess weightSubclinical atherosclerosisOdds ratioFatty massMuscle massPhysical performance testsCoronary heart disease riskElderly individualsRisk of coronary heart diseaseAssociated with coronary heart diseaseCaloric intakeIncreased risk of coronary heart diseaseStudy of CohortsEndothelial dysfunctionCross-sectional studySkeletal muscle indexAssociated with flow-mediated dilationGait speedCardiac computed tomographyReduction of muscle massMultivariate regression model
2016
TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction
Cintra R, Moura F, Carvalho L, Daher M, Santos S, Costa A, Figueiredo V, Andrade J, Neves F, Quinaglia e Silva J, Sposito A, Group O. TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction. BBA Clinical 2016, 5: 159-165. PMID: 27213136, PMCID: PMC4865630, DOI: 10.1016/j.bbacli.2016.03.010.Peer-Reviewed Original ResearchC-reactive proteinFlow-mediated dilationST-elevation MIInterleukin-2Myocardial infarctionInsulin secretionCapacity of insulin secretionNitric oxideAssociated with lower insulin secretionHigher 30-day mortalityNon-diabetic STEMI patientsNon-diabetic patientsT allele carriersTranscription factor 7-like 2Influence clinical outcomesEnhanced inflammatory responseTCF7L2 gene polymorphismPlasma interleukin-2Short-term mortalityEndogenous insulin secretionNitric oxide releaseLower insulin secretionExogenous insulin administrationNitric oxide changesRs7903146 polymorphism
2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryCoronary AngiographyC-Reactive ProteinDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2014
Low zinc levels is associated with increased inflammatory activity but not with atherosclerosis, arteriosclerosis or endothelial dysfunction among the very elderly
De Paula RC, Aneni EC, Costa AP, Figueiredo VN, Moura FA, Freitas WM, Quaglia LA, Santos SN, Soares AA, Nadruz W, Blaha M, Blumenthal R, Agatston A, Nasir K, Sposito AC, Group O. Low zinc levels is associated with increased inflammatory activity but not with atherosclerosis, arteriosclerosis or endothelial dysfunction among the very elderly. BBA Clinical 2014, 2: 1-6. PMID: 26676114, PMCID: PMC4633969, DOI: 10.1016/j.bbacli.2014.07.002.Peer-Reviewed Original ResearchFlow-mediated dilationC-reactive proteinDaily intakeEndothelial dysfunctionInflammatory activityCoronary plaquesPlasma levelsPlasma zincCarotid intima-media thicknessZinc levelsArterial wallNoncalcified coronary plaquesAnti-inflammatory treatmentCarotid plaque presenceCRP plasma levelsPlasma CRP levelsSystemic inflammatory activityCoronary calcium scoreIntima-media thicknessCardiac computed tomographyPlasma zinc levelsSignificant differencesLow zinc levelsAverage daily intakeAtherosclerotic burdenShort-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial
Figueiredo V, Vendrame F, Colontoni B, Quinaglia T, Matos-Souza J, Moura F, Coelho O, de Faria E, Sposito A. Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. Clinical Therapeutics 2014, 36: 961-966. PMID: 24768191, DOI: 10.1016/j.clinthera.2014.03.012.Peer-Reviewed Original ResearchConceptsEffects of extended-release niacinFlow-mediated dilationExtended-release niacinHDL-C levelsHDL-CEndothelial functionDay 7Reduced plasma concentrations of high-density lipoprotein cholesterolLow HDL-C levelsHDL-C levels <Plasma concentrations of high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolConcentrations of high-density lipoprotein cholesterolLow HDL-C.Low HDL-CHeme oxygenase-1 pathwayTreatment period 1C-reactive proteinPlasma HDL-CTreatment period 2Improving endothelial functionEffects of niacinTransfer protein activityShort-term effectsReduced plasma concentrations